TY - JOUR
T1 - Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials
AU - Nagamani, Sandesh C.S.
AU - Diaz, George A.
AU - Rhead, William
AU - Berry, Susan A.
AU - Le Mons, Cynthia
AU - Lichter-Konecki, Uta
AU - Bartley, James
AU - Feigenbaum, Annette
AU - Schulze, Andreas
AU - Longo, Nicola
AU - Berquist, William
AU - Gallagher, Renata
AU - Bartholomew, Dennis
AU - Harding, Cary O.
AU - Korson, Mark S.
AU - McCandless, Shawn E.
AU - Smith, Wendy
AU - Vockley, Jerry
AU - Kronn, David
AU - Zori, Robert
AU - Cederbaum, Stephen
AU - Lawrence Merritt, J.
AU - Wong, Derek
AU - Coakley, Dion F.
AU - Scharschmidt, Bruce F.
AU - Dickinson, Klara
AU - Marino, Miguel
AU - Lee, Brendan H.
AU - Mokhtarani, Masoud
N1 - Funding Information:
The authors gratefully acknowledge and thank the efforts of the study staff who made this study possible, including N. Schrager (Icahn School of Medicine at Mount Sinai), A. Donovan, J. Crawford, Pediatric TRU Staff, K. Defouw, J. Balliet (The Medical College of Wisconsin), M. Keuth, N. O'Donnell (Long Beach Memorial Hospital), M. Hussain, E. Bailey, A. Orton, M. Ambreen (The Hospital for Sick Children, University of Toronto, ON, Canada), C. Bailey, M.J. Dunkley (The University of Utah), J. Perry, V. de Leon, A. Niemi, K. Cusmano (Stanford University), T. Carlson, J. Parker (University of Minnesota), S. Burr (Children's Hospital Colorado), K. Simpson (Children's National Medical Center), K. Regis (Nationwide Children's Hospital), A. Behrend, T. Marrone (Oregon Health & Sciences University), N. Dorrani (University of California, Los Angeles), C. Heggie (Case Western Reserve University), S. Mortenson (Maine Medical Center), S. Deward (Children's Hospital of Pittsburgh), K. Bart, C. Duggan (SNBL), K. Murray, C. Dedomenico (Tufts Medical Center), C. Gross (University of Florida), L. Brody (Seattle Children's Hospital), M. Mullins, S. Carter, A. Tran, J. Stuff, TCH General Clinical Research Center nursing staff (Baylor), Kathy Lisam (Hyperion), as well as the Clinical and Translational Science Awards/General Clinical Research Center Grants (Baylor College of Medicine, M01RR00188; Case Western Reserve University, NIDDK 1K08DK074573; Clinical and Translational Science Institute at Children's National Medical Center NIH/NCRR, UL1RR31988; Medical College of Wisconsin, UL1RR31973; Mount Sinai School of Medicine, UL1RR29887; Oregon Health & Science University, UL1RR24140; Stanford University, UL1RR25744; Tufts University, UL1RR25752; University of California, Los Angeles, UL1RR33176; University of Colorado, UL1RR25780; University of Florida, UL1RR29890; University of Minnesota, UL1RR33183; University of Pittsburgh, NIH UL1TR000005; University of Utah, UL1RR25764; University of Washington,UL1TR000423), the Urea Cycle Disorders Consortium (NIH Grant U54RR019453) and grants from the O'Malley Foundation, Kettering Fund, and Rotenberg Fund which provided support. SCS Nagamani is an awardee of the National Urea Cycle Disorders Foundation Research Fellowship and is supported by the Clinical Scientist Development Award by the Doris Duke Charitable Foundation. Appendix A
Publisher Copyright:
© 2015 Elsevier Inc..
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Background: Health care outcomes have been increasingly assessed through health-related quality of life (HRQoL) measures. While the introduction of nitrogen-scavenging medications has improved survival in patients with urea cycle disorders (UCDs), they are often associated with side effects that may affect patient compliance and outcomes. Methods: Symptoms commonly associated with nitrogen-scavenging medications were evaluated in 100 adult and pediatric participants using a non-validated UCD-specific questionnaire. Patients or their caregivers responded to a pre-defined list of symptoms known to be associated with the use of these medications. Responses were collected at baseline (while patients were receiving sodium phenylbutyrate [NaPBA]) and during treatment with glycerol phenylbutyrate (GPB). Results: After 3. months of GPB dosing, there were significant reductions in the proportion of patients with treatment-associated symptoms (69% vs. 46%; p < 0.0001), the number of symptoms per patient (2.5 vs. 1.1; p < 0.0001), and frequency of the more commonly reported individual symptoms such as body odor, abdominal pain, nausea, burning sensation in mouth, vomiting, and heartburn (p < 0.05). The reduction in symptoms was observed in both pediatric and adult patients. The presence or absence of symptoms or change in severity did not correlate with plasma ammonia levels or NaPBA dose. Conclusions: The reduction in symptoms following 3. months of open-label GPB dosing was similar in pediatric and adult patients and may be related to chemical structure and intrinsic characteristics of the product rather than its effect on ammonia control.
AB - Background: Health care outcomes have been increasingly assessed through health-related quality of life (HRQoL) measures. While the introduction of nitrogen-scavenging medications has improved survival in patients with urea cycle disorders (UCDs), they are often associated with side effects that may affect patient compliance and outcomes. Methods: Symptoms commonly associated with nitrogen-scavenging medications were evaluated in 100 adult and pediatric participants using a non-validated UCD-specific questionnaire. Patients or their caregivers responded to a pre-defined list of symptoms known to be associated with the use of these medications. Responses were collected at baseline (while patients were receiving sodium phenylbutyrate [NaPBA]) and during treatment with glycerol phenylbutyrate (GPB). Results: After 3. months of GPB dosing, there were significant reductions in the proportion of patients with treatment-associated symptoms (69% vs. 46%; p < 0.0001), the number of symptoms per patient (2.5 vs. 1.1; p < 0.0001), and frequency of the more commonly reported individual symptoms such as body odor, abdominal pain, nausea, burning sensation in mouth, vomiting, and heartburn (p < 0.05). The reduction in symptoms was observed in both pediatric and adult patients. The presence or absence of symptoms or change in severity did not correlate with plasma ammonia levels or NaPBA dose. Conclusions: The reduction in symptoms following 3. months of open-label GPB dosing was similar in pediatric and adult patients and may be related to chemical structure and intrinsic characteristics of the product rather than its effect on ammonia control.
KW - Ammonia
KW - Glycerol phenylbutyrate
KW - Health-related quality of life
KW - Patient-reported outcomes
KW - Sodium phenylbutyrate
KW - Treatment-related symptoms
UR - http://www.scopus.com/inward/record.url?scp=84940895916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940895916&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2015.08.002
DO - 10.1016/j.ymgme.2015.08.002
M3 - Article
C2 - 26296711
AN - SCOPUS:84940895916
VL - 116
SP - 29
EP - 34
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
SN - 1096-7192
IS - 1-2
ER -